3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Breast Neoplasms
4
Neoplasm Metastasis
3
Cholangiocarcinoma
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Urologic Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Adenocarcinoma Metastatic
1
Pancreatic Adenocarcinoma
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
MMR-D/MSI-H Colorectal Cancers
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Anus Neoplasms
1
Interventions
Gemcitabine
13
Albumin-Bound Paclitaxel
8
Taxes
6
130-nm albumin-bound paclitaxel
6
Fluorouracil
5
Oxaliplatin
4
dehydroftorafur
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Leucovorin
3
Irinotecan
3
Losartan
2
Cisplatin
2
tocilizumab
1
selicrelumab
1
niraparib
1
irinotecan sucrosofate
1
indusatumab
1
folfirinox
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
S 1 (combination)
1
Resistance Training
1
Radiotherapy, Image-Guided
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Adenocarcinoma
×
niraparib
×
Gastrointestinal
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts